Drug
HS 10296
HS 10296: highest development phase Phase 1/2, developed by Hansoh Pharmaceutical. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Hansoh Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| HS-10296 NCT02981108 | Phase 1/2 | Nonsmall Cell Lung Cancer |
Latest
No recent events.
Follow HS 10296 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.